Amgen-Novartis data demonstrate LT efficacy of Aimovig for migraine

Amgen (AMGN) And Novartis (NVS) present new data demonstrating long-term efficacy, safety and tolerability of Aimovig In patients with chronic and episodic migraine. — Amgen announced that the results of two open-label extension, OLE, studies of Aimovig in patients with chronic and episodic migraine, respectively, will be presented at the 60th Annual Scientific Meeting of the American Headache Society in San Francisco. Results from a one-year study in chronic migraine patients reinforced the established safety and efficacy profile of Aimovig in long-term use. In addition, a three-year interim analysis from an ongoing five-year study of episodic migraine patients, the longest running study of a calcitonin gene-related peptide therapy, reinforced the long-term safety and tolerability of Aimovig. Aimovig is the first and only FDA-approved therapy targeting the CGRP pathway. In the one-year OLE study in chronic migraine, the primary and secondary outcome measures of the study were long-term safety and efficacy, respectively.1 The safety results after one year were consistent with the established safety profile of Aimovig in previous studies. The most frequent adverse events greater than 2.0 per 100-subject-years were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, arthralgia and migraine. In the double-blind treatment phase, no differences were observed in the safety events between Aimovig and placebo. In August 2015, Amgen entered into a global collaboration with Novartis to develop and commercialize pioneering treatments in the field of migraine and Alzheimer's.
https://bit.ly/2IAsz1i